Study the effect of gene polymorphism contribution of statin biotransformation and lipid metabolism for parameters of statin efficacy. Recruiting

Abstract

Rosuvastatin is high-performance hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, which commonly used in the treatment of hyperlipidemia. It significantly reduces levels of LDL, which accompanied by a moderate increase in HDL and a decrease triglycerides in blood serum. Nowadays rozuvastatin is the safest among statin preparation and it differs from simvastatin, lovastatin and atorvastatin by minimal hepatic metabolism. Endogenous characteristics of drugs metabolism, which depends on polymorphisms of transformation genes and statin transportation, can reflect on achievement of final efficacy. Individual variability in the effectiveness and safety of drugs is one of the topical problems of clinical practice. It is known that genetic variations are factors in determining an individual response to drug therapy. There are many examples of cause-effect relationships between genotype and response to drug therapy. Based on written above, the purpose of this study is to research the pharmacokinetic characteristics of the therapy with rosuvastatin.